Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Who May Qualify: - Diagnosis of MG confirmed by: - History of a positive serologic test for anti-AChR antibodies, and - One of the following: - History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation - History of positive anticholinesterase test (e.g., edrophonium chloride test); or - Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician - Disease duration from MG onset ≤ 3 years before T-4 (Enrolment); - MGFA class IIb to IV; - Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria - Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC. Who Should NOT Join This Trial: - Patient unable to understand and sign the willing to sign a consent form - Hypersensitivity to the active substance or to any of the excipients of the study product - Patient for whom the study product is contraindicated according to SmPC - Previous treatment with C5 inhibitors - Last rituximab infusion performed \< 6 months before T-4 (Enrolment) - Last infusion with FcRn blockers performed \< 3 months before T-4 (Enrollment) - Pregnant or lactating or planning a pregnancy during the study - Patient who plan to relocate during the study - Patient who are unsure of following the visit schedule - Patient unable to complete questionnaires - Previous or current participation to other interventional studies Always talk to your doctor about whether this trial is right for you.